TipRanks
Advertisement
Advertisement

BIIB Stock Latest News

Biogen publishes results from adolescent subgroup of VALIANT study
The FlyBiogen publishes results from adolescent subgroup of VALIANT study
2d ago
BIIB
Eisai, Biogen announce Leqembi Pen has been approved in Japan
PremiumThe Fly
Eisai, Biogen announce Leqembi Pen has been approved in Japan
3d ago
BIIB
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
PremiumThe Fly
Private Markets: Gimlet Labs, Encoded Therapeutics secure new funding
9d ago
GS
MS
Biogen price target raised to $175 from $165 at HSBC
PremiumThe Fly
Biogen price target raised to $175 from $165 at HSBC
9d ago
BIIB
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
PremiumThe Fly
Stoke Therapeutics, Biogen present long-term data on Zorevunersen
16d ago
BIIB
STOK
Biogen price target raised to $245 from $225 at Piper Sandler
PremiumThe FlyBiogen price target raised to $245 from $225 at Piper Sandler
16d ago
BIIB
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
Premium
The Fly
Biogen, Eisai announce NMPA of China approves subcutaneous Leqembi
16d ago
BIIB
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
Premium
The Fly
Stoke Therapeutics, Biogen present clinical data of Dravet syndrome candidate
18d ago
BIIB
STOK
Biogen, Eisai announce positive recommendation for Leqembi in Canada
PremiumThe Fly
Biogen, Eisai announce positive recommendation for Leqembi in Canada
19d ago
BIIB
Veeva price target raised to $310 from $270 at Needham
PremiumThe Fly
Veeva price target raised to $310 from $270 at Needham
23d ago
LLY
BIIB
Biogen price target raised to $260 from $240 at RBC Capital
PremiumThe Fly
Biogen price target raised to $260 from $240 at RBC Capital
25d ago
BIIB
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
PremiumThe Fly
Eisai, Biogen announces once weekly lecanemab-irmb availability in the U.S.
26d ago
BIIB
Biogen, Eisai announce Leqembi Iqlik now available in U.S.
PremiumThe FlyBiogen, Eisai announce Leqembi Iqlik now available in U.S.
26d ago
BIIB
Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial
Premium
Company Announcements
Biogen Expands Autoimmune Pipeline With New Graves’ Disease Trial
29d ago
BIIB
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
Premium
The Fly
ProMIS Neurosciences price target lowered to $29 from $30 at Roth Capital
29d ago
PMN
BIIB
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
PremiumThe Fly
Biogen upgraded to Outperform from Peer Perform at Wolfe Research
1M ago
BIIB
Wolfe upgrades Biogen to Outperform on late-stage pipeline
PremiumThe Fly
Wolfe upgrades Biogen to Outperform on late-stage pipeline
1M ago
BIIB
Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
PremiumThe Fly
Five Below upgraded, StubHub downgraded: Wall Street’s top analyst calls
1M ago
OI
ALC
Biogen’s Long-Term Spinraza Study Wraps Up, Setting the Stage for Key SMA Data
PremiumCompany Announcements
Biogen’s Long-Term Spinraza Study Wraps Up, Setting the Stage for Key SMA Data
1M ago
BIIB
Insiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab
PremiumWeekend UpdatesInsiders Shake Up General Dynamics, Thermo Fisher, Carvana, Biogen, Charles Schwab
1M ago
GD
TMO
Biogen completes acquisition of RayThera
Premium
The Fly
Biogen completes acquisition of RayThera
1M ago
BIIB
Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story
Premium
Company Announcements
Biogen Extends Felzartamab Kidney Rejection Trial, Bolstering Long-Term Pipeline Story
1M ago
BIIB

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >